Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Cardinal Health, Inc.    CAH

CARDINAL HEALTH, INC.

(CAH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
47.9(c) 47.71(c) 47.83(c) 48.77(c) 49.34(c) Last
1 791 457 1 678 557 1 294 435 1 396 519 1 284 651 Volume
-1.82% -0.40% +0.25% +1.97% +1.17% Change
More quotes
Financials (USD)
Sales 2021 159 B - -
Net income 2021 1 271 M - -
Net Debt 2021 2 865 M - -
P/E ratio 2021 12,0x
Yield 2021 4,01%
Sales 2022 166 B - -
Net income 2022 1 358 M - -
Net Debt 2022 1 709 M - -
P/E ratio 2022 10,9x
Yield 2022 4,11%
Capitalization 14 476 M 14 476 M -
EV / Sales 2021 0,11x
EV / Sales 2022 0,10x
Nbr of Employees 48 000
Free-Float 89,4%
More Financials
Company
Cardinal Health is specialized in the distribution of products and health services to pharmacies, hospitals and medical practices. Net sales break down by activity as follows: - distribution of pharmaceutical products (88.6%); - distribution of medical, surgical and laboratory products (11.4%). The group also develops a manufacturing of medical and surgical products activity (masks, overalls, gloves, diagnostic... 
Sector
Drug Retailers
Calendar
11/04 | 10:00amShareholder meeting
More about the company
Notations Surperformance© of Cardinal Health, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about CARDINAL HEALTH, INC.
10/22Walmart Files Pre-emptive Lawsuit Against Federal Government in Opioid Case
DJ
10/22Walmart Files Pre-emptive Lawsuit Against Federal Government in Opioid Case -..
DJ
10/19CARDINAL HEALTH : Upsher-Smith's Brad Leonard and Amy Dearborn Honored by Cardin..
AQ
10/13J&J to contribute up to $5 billion to potential U.S. opioid settlement
RE
10/01All Remdesivir Supplies to Be Distributed in U.S. by Maker Gilead Sciences --..
DJ
10/01All Remdesivir Supplies to Be Distributed in U.S. by Maker Gilead Sciences
DJ
09/30CARDINAL HEALTH, INC. : Ex-dividend day for
FA
09/25CARDINAL HEALTH : to Webcast Discussion of First-Quarter Results for Fiscal Year..
PR
09/25CARDINAL HEALTH : Sheri Edison to join Cardinal Health Board of Directors
PU
09/24U.S. appeals court rejects novel opioid settlement framework
RE
08/31CARDINAL HEALTH INC : Change in Directors or Principal Officers, Regulation FD D..
AQ
08/19States Press Opioid Litigation -- WSJ
DJ
08/18Health Care Flat As Opioid Lawsuit Settlements Loom -- Health Care Roundup
DJ
08/18States Seek $26.4 Billion From Drug Companies in Opioid Litigation
DJ
08/18U.S. States Seek $26.4 Bln From Drug Companies In Opioid Litigation - WSJ
RE
More news
News in other languages on CARDINAL HEALTH, INC.
10/23CRISE DES OPIACÉS : le géant Walmart attaque le ministère américain de la Justic..
08/18WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
03/06Ramelow stimmte für AfD-Landtagsvize - Parlamentsrechte wahren
02/27AKTIE IM FOKUS 2 : Vorsichtiger Ausblick und schwacher Markt setzen Bayer zu
02/21Daimler met en garde contre les conséquences du coronavirus
More news
Analyst Recommendations on CARDINAL HEALTH, INC.
More recommendations
Chart CARDINAL HEALTH, INC.
Duration : Period :
Cardinal Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARDINAL HEALTH, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 59,20 $
Last Close Price 49,34 $
Spread / Highest target 29,7%
Spread / Average Target 20,0%
Spread / Lowest Target 1,34%
EPS Revisions
Managers
NameTitle
Michael C. Kaufmann Chief Executive Officer & Director
Gregory B. Kenny Independent Non-Executive Chairman
Jason M. Hollar Chief Financial Officer
Brian S. Rice Chief Information Officer & Executive VP
J. Michael Losh Independent Director
Sector and Competitors